All News
More data from PAISLEY, deucravacitinib in SLE
Small but significant benefit w/respect to joints, a little disappointing tbh
Would like to see this for all manifestations ie pericarditis, pleuritis, etc
Anyone have an infographic or useful chart?
#ACR20 @RheumNow Abstr#1552 https://t.co/tXUoUtssxo
Links:
Mike Putman EBRheum ( View Tweet)
Low uptake of SGLT2i in Lupus nephritis
SGLT2i users had similar adverse event rates as ACEi/ARB users
SGLT2i users experienced more weight loss
#ACR24 @rheumnow abst#1534 https://t.co/tB5o7tyhu5
Bella Mehta bella_mehta ( View Tweet)
Study on SLE and NMO overlap:
Higher risk of acute cystitis & severe sepsis in hospitalized patients
SLE/NMO overlap patients 3x more likely to develop acute cystitis
2x more likely to develop severe sepsis #ACR24 @RheumNow abst#1529
Bella Mehta bella_mehta ( View Tweet)
Study on SLE treatments:
Compared adverse events of anifrolumab vs. belimumab
Similar risks for mortality, sepsis, herpes zoster, dialysis, MACE, PE/VTE, COVID-19, URI, pneumonia, and mental illness #ACR24 @RheumNow abst#1527
Bella Mehta bella_mehta ( View Tweet)
Smoking and Rx progression in PsA?
-Prospective Canadian cohort of 1736 PsA pts.
-Older age, BL SJC, dactylitis, erosions and high ESR were associated with Rx progression.
🚨Cigarette smoking did not appear to be associated with the Rx progression in PsA.
Abst#1436 #ACR24… https://t.co/J2IogqOlx8 https://t.co/U6SRmbOE6o
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Study on severe lymphopenia in SLE:
- Assessed incidence, risk factors, and outcomes
- 11.52% of SLE patients experienced severe lymphopenia
- Higher infection rates during severe lymphopenia period
= No opportunistic infections observed #ACR24 abst#1519 @rheumnow @HSSProfEd
Bella Mehta bella_mehta ( View Tweet)
Study on pregnancy outcomes in SLE with thrombocytopenia:
Higher disease activity, pregnancy loss, and stillbirth rates
Identified risk factors: Anti-β2GP-I positivity and higher SLEDAI score #ACR24 abst#1487 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Study on cardiovascular deaths in SLE:
- Analyzed 1999-2020 data
- Overall decline in mortality rates, but recent increase since 2014
- Higher rates in women and African Americans
- Geographic disparities noted
#ACR24 abst#0998 @rheumnow https://t.co/dpjsl0gI0x
Links:
Bella Mehta bella_mehta ( View Tweet)
Post hoc analysis of INVIGORATE-1 trial evaluated predictors of ASAS40 response in axSpA pts who received IV SEC
⬆️back pain, long dse duration, ⬇️BMI: assoc w/ ⬆️ clinical response
BL enthesitis, older age, ⬆️dse activity: assoc w/ ⬇️ clinical response
@RheumNow #ACR24 abs1482 https://t.co/528A5lXVKl
Links:
sheila RHEUMarampa ( View Tweet)
#Upadacitinib rises ‘ Up’ in all subgroups of #GCA Subset of overall #RCT of #rinvoq w more reduction of #steroids vs placebo+ slower #prednisone taper Consistent results best in UPA 15 mg >UPA 7.5mg/d > #placebo #ACR24 #ACRBest @RheumNow @ACRheum abst#1695 https://t.co/dA7RkNmWFd
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Salivary glands in #Sjogens #Disease
Have persistent
#IFN signature
Abnormal morphology
⬇️ secretory ability
In
Differentiated salivary gland organoids
DSGO
May aid in drug screening
Would drugs that
⬇️ #interferon help #Sjogren’s
Abst#1406 @RheumNow @ACRheum #ACR24 https://t.co/dppp0tyFk5
Janet Pope Janetbirdope ( View Tweet)
Alright help me out here; this is pretty implausible, right?
Why would be pts be 11% more adherent to UPA? What's the bio-plausibility here? UPA 10% better than other JAKs?
Could do a network meta analysis; betting this doens't replicate
#ACR24 @RheumNow Abstr#1362 https://t.co/vpPq3vu9Wf
Links:
Mike Putman EBRheum ( View Tweet)
#Rheumatoid #arthritis is an independent risk factor for death in nonmetastatic clear cell renal ca !
👇N=32K, 802 w RA also
Caveats
immunotherapy Offered = in RA
Cancer specific mortality not affected
By #RA
Frailty & RA affected outcomes
#ACR24 @RheumNow @ACRheum #1327 https://t.co/rAQ57BPA19
Janet Pope Janetbirdope ( View Tweet)
The Joint Project is a community-based, barangay health worker-led screening program that aims to increase MSK dse awareness, timely referral & treatment or rehab.
The figure below illustrates the conceptual framework for the program
@RheumNow #ACR24 abs0979 https://t.co/yxXsASl2GJ
sheila RHEUMarampa ( View Tweet)
This study by Dr. UGazel et al shows that cervical DISH in SpA is similar to the general population.
Of note, HLAB27+ axSpA pts had more DISH while PsA pts had DISH if they were HLaB27(-)
@RheumNow #ACR24 abs1447 https://t.co/GtcvxVSb8B
sheila RHEUMarampa ( View Tweet)
Gonzalez Molina et al. MANHATTAN observational study. In PsA after 1st TNFi failure should we use guselkumab or 2nd TNFi? Guselkumab slightly better persistence, DAPSA, and improvements in joint counts. @RheumNow #ACR24 Abstr#1469 https://t.co/X3TMCVys6B https://t.co/vvkUYbzVDq
Links:
Richard Conway RichardPAConway ( View Tweet)
Ultrasound guided injections on cadavers improve rheumatology trainees ability to do
#joint #injections
17 trainees -a couple of hrs of cadaver inj
▶️ joint injection confidence improved esp uncommon / difficult areas
Elbow
Ankle
Wrist
@RheumNow #ACR24 @ACRheum abst#1310 https://t.co/ZcER4s8QcR
Janet Pope Janetbirdope ( View Tweet)
No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients
UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse… https://t.co/IOzckJIfYf https://t.co/8S6FnffVLG
Dr. John Cush RheumNow ( View Tweet)
TYK2/JAK1 in Dermato? Interesting pre-clinical study of brepocitinib... but we really just need clinical data
Glad to see this is headed straight to a Phase 3! Hoping they allow IVIG: has been a problem with many/most/all? recent dermato studies
#ACR24 @RheumNow Abstr#0882 https://t.co/KS8fTMBpPR
Mike Putman EBRheum ( View Tweet)